[{"id":"eda22fa5-a154-4718-aaaf-d2fb8460e402","acronym":"","url":"https://clinicaltrials.gov/study/NCT02721459","created_at":"2021-01-18T13:18:50.231Z","updated_at":"2025-02-25T16:30:48.412Z","phase":"Phase 1","brief_title":"XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma","source_id_and_acronym":"NCT02721459","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib) • XL888"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/07/2016","start_date":" 09/07/2016","primary_txt":" Primary completion: 10/31/2019","primary_completion_date":" 10/31/2019","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-07"},{"id":"5e8d91ea-f7f3-439a-aea4-8b3ad3fa4f77","acronym":"","url":"https://clinicaltrials.gov/study/NCT01657591","created_at":"2021-01-18T07:08:59.902Z","updated_at":"2024-07-02T16:35:57.422Z","phase":"Phase 1","brief_title":"Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma","source_id_and_acronym":"NCT01657591","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • XL888"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 07/27/2012","start_date":" 07/27/2012","primary_txt":" Primary completion: 09/20/2016","primary_completion_date":" 09/20/2016","study_txt":" Completion: 09/21/2021","study_completion_date":" 09/21/2021","last_update_posted":"2023-01-19"}]